Drug Profile
Research programme: cardioprotective peptides - Eribis Pharmaceuticals
Alternative Names: CD 94; CD peptide 94Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eribis Pharmaceuticals
- Class Peptides
- Mechanism of Action Opioid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Myocardial-infarction in Sweden (IV, Injection)